How Devices Get Sold: Physician Preference, GPOs, and Hospital Purchasing

Introduction

The medical device sales process is unlike any other in healthcare. In pharma, the prescribing physician is the primary decision-maker but the drug is purchased through a pharmacy/PBM supply chain. In healthcare services, the payer is the primary revenue source. In MedTech, the purchasing decision involves a three-way dynamic among the surgeon (who selects the device), the hospital (who negotiates the price), and the sales representative (who provides clinical support in the operating room). Understanding this dynamic is essential for modeling device company revenue and assessing competitive moats.

Physician Preference Item (PPI)

A medical device that the physician (typically a surgeon) selects based on clinical training, familiarity, and personal preference rather than hospital purchasing committee mandate. PPIs include surgical implants (joint replacements, spinal hardware, cardiac devices), instruments, and consumables used in procedures. PPIs are the highest-margin device category and the most defensible competitively because switching requires surgeon retraining. Hospitals have historically had limited ability to standardize PPIs because surgeons can threaten to move cases to competing facilities.

The PPI dynamic creates a unique competitive moat. A surgeon who trained on Stryker hip implants during residency and has performed 500+ procedures with those implants is unlikely to switch to a Zimmer Biomet implant unless there is a compelling clinical reason. This training-driven lock-in means market share changes in PPI categories happen slowly (1-2% per year), typically driven by next-generation product launches or surgeon retirement/recruitment.

GPOs negotiate device pricing on behalf of their member hospitals, aggregating volume across hundreds or thousands of facilities to extract discounts from device manufacturers. The top GPOs (Vizient, Premier, HealthTrust, GNYHA) cover over 90% of US hospitals. Note that the GPO market has consolidated significantly (Vizient acquired Intalere in 2021).

How GPO contracts work. GPOs negotiate tiered pricing contracts where hospitals receive greater discounts at higher purchasing volumes. A typical GPO contract for surgical staplers might offer a 15% discount at baseline volume, 25% at 150% of baseline, and 35% at 200%. These contracts typically run 3-5 years with annual price escalators (or more commonly, flat or declining pricing).

MedTech sales representatives play a role that does not exist in other industries: they are often present in the operating room during procedures, providing technical guidance to surgeons on device implantation. This "in the OR" presence creates deep relationships, real-time feedback loops, and a competitive moat that is difficult to replicate.

The cost is significant. A well-compensated MedTech sales rep earns $150,000-$400,000+ in total compensation (base plus commission), and large device companies employ 3,000-15,000 reps. This explains why SG&A as a percentage of revenue (25-35%) is higher in MedTech than in most healthcare sub-sectors.

The next article covers medical device reimbursement, the critical link between FDA clearance and actual revenue generation.